The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
IL-23 promotes tumour incidence and growth
Abstract
Chronic inflammation has long been associated with increased incidence of malignancy and similarities in the regulatory mechanisms have been suggested for more than a century. Infiltration of innate immune cells, elevated activities of matrix metalloproteases and increased angiogenesis and vasculature density are a few examples of the similarities between chronic and tumour-associated inflammation. Conversely, the elimination of early malignant lesions by immune surveillance, which relies on the cytotoxic activity of tumour-infiltrating T cells or intra-epithelial lymphocytes, is thought to be rate-limiting for the risk to develop cancer. Here we show a molecular connection between the rise in tumour-associated inflammation and a lack of tumour immune surveillance. Expression of the heterodimeric cytokine interleukin (IL)-23, but not of its close relative IL-12, is increased in human tumours. Expression of these cytokines antagonistically regulates local inflammatory responses in the tumour microenvironment and infiltration of intra-epithelial lymphocytes. Whereas IL-12 promotes infiltration of cytotoxic T cells, IL-23 promotes inflammatory responses such as upregulation of the matrix metalloprotease MMP9, and increases angiogenesis but reduces CD8 T-cell infiltration. Genetic deletion or antibody-mediated elimination of IL-23 leads to increased infiltration of cytotoxic T cells into the transformed tissue, rendering a protective effect against chemically induced carcinogenesis. Finally, transplanted tumours are growth-restricted in hosts depleted for IL-23 or in IL-23-receptor-deficient mice. Although many strategies for immune therapy of cancer attempt to stimulate an immune response against solid tumours, infiltration of effector cells into the tumour tissue often appears to be a critical hurdle. We show that IL-23 is an important molecular link between tumour-promoting pro-inflammatory processes and the failure of the adaptive immune surveillance to infiltrate tumours.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-17 also induces proliferative signaling in keratinocytes through Act1, a major facet of its impact in psoriasis and perhaps also explaining its involvement in skin tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“this pro-proliferative role likely contributes to the pathogenic effects of IL-17 in psoriasis, as well as potentially in skin cancer”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
In the citing paper
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis”
From The IL-17 Family of Cytokines in Health and Disease (2019) · cites this paper as Langowski et al., 2006
Citations
Cites
Coussens, L. M., & Werb, Z. (2002) · Nature · doi:10.1038/nature01322 · Cited by 15,111
Inflammation and cancer: back to Virchow?
Balkwill, F., & Mantovani, A. (2001) · The Lancet · doi:10.1016/s0140-6736(00)04046-0 · Cited by 7,746
Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005) · Nature Immunology · doi:10.1038/ni1254 · Cited by 4,742
IL-23 drives a pathogenic T cell population that induces autoimmune inflammation
Langrish, C. L., Chen, Y., Blumenschein, W. M., Mattson, J., Basham, B., Sedgwick, J. D., McClanahan, T., Kastelein, R. A., & Cua, D. J. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20041257 · Cited by 4,099
Self-citationInterleukin-12 and the regulation of innate resistance and adaptive immunity
Trinchieri, G. (2003) · Nature Reviews Immunology · doi:10.1038/nri1001 · Cited by 3,927
The Immunobiology of Cancer Immunosurveillance and Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.017 · Cited by 3,032
Cua, D. J., Sherlock, J., Chen, Y., Murphy, C. A., Joyce, B., Seymour, B., Lucian, L., To, W., Kwan, S., Churakova, T., et al. (2003) · Nature · doi:10.1038/nature01355 · Cited by 2,906
Self-citationOppmann, B., Lesley, R., Blom, B., Timans, J. C., Xu, Y., Hunte, B., Vega, F., Yu, N., Wang, J., Singh, K., et al. (2000) · Immunity · doi:10.1016/s1074-7613(00)00070-4 · Cited by 2,822
Self-citationMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Aggarwal, S., Ghilardi, N., Xie, M.-H., de Sauvage, F. J., & Gurney, A. L. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207577200 · Cited by 1,847
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Immunity, Inflammation, and Cancer
Grivennikov, S. I., Greten, F. R., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2010.01.025 · Cited by 10,755
“…subsets found in solid tumors are involved in tumor promotion, progression, or metastasis, including CD8+ T cells (Roberts et al., 2007), IFNγ-producing Th1 cells (Hanada et al., 2006), Th2 cells (Aspord et al., 2007; DeNardo et al., 2009) and Th17 cells (Langowski et al., 2006; Wang et al., 2009).”
InfluentialIvanov, I. I., McKenzie, B. S., Zhou, L., Tadokoro, C. E., Lepelley, A., Lafaille, J. J., Cua, D. J., & Littman, D. R. (2006) · Cell · doi:10.1016/j.cell.2006.07.035 · Cited by 5,145
STATs in cancer inflammation and immunity: a leading role for STAT3
Yu, H., Pardoll, D., & Jove, R. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2734 · Cited by 4,383
Cancer Metastasis: Building a Framework
Gupta, G. P., & Massagué, J. (2006) · Cell · doi:10.1016/j.cell.2006.11.001 · Cited by 4,247
“However, this potent response is frequently blunted during the progression of neoplasms by the tumor-derived overexpression of immunosuppressive cytokines such as TGF-β, interleukin-10, and interleukin-23 (Gorelik and Flavell, 2002; Langowski et al., 2006; Zou, 2005).”
BackgroundInflammation and tumor progression: signaling pathways and targeted intervention
Zhao, H., Wu, L., Yan, G., Chen, Y., Zhou, M., Wu, Y., & Li, Y. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00658-5 · Cited by 2,792
Self-citationCancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
“as IL-1β, IL-6 and TNF-α [11-14].”
Natural Innate and Adaptive Immunity to Cancer
Vesely, M. D., Kershaw, M. H., Schreiber, R. D., & Smyth, M. J. (2011) · Annual Review of Immunology · doi:10.1146/annurev-immunol-031210-101324 · Cited by 2,101
Tumor microenvironment as a therapeutic target in cancer
Xiao, Y., & Yu, D. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 1,957
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
A cytokine-mediated link between innate immunity, inflammation, and cancer
Lin, W.-W., & Karin, M. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31537 · Cited by 1,940
“Animal studies have so far revealed contradictory effects of IL-23 on tumor growth (85–87).”
InfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Wu, S., Rhee, K.-J., Albesiano, E., Rabizadeh, S., Wu, X., Yen, H.-R., Huso, D. L., Brancati, F. L., Wick, E., McAllister, F., et al. (2009) · Nature Medicine · doi:10.1038/nm.2015 · Cited by 1,812
The biology of innate lymphoid cells
Artis, D., & Spits, H. (2015) · Nature · doi:10.1038/nature14189 · Cited by 1,634
Inflammation in prostate carcinogenesis
De Marzo, A. M., Platz, E. A., Sutcliffe, S., Xu, J., Grönberg, H., Drake, C. G., Nakai, Y., Isaacs, W. B., & Nelson, W. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2090 · Cited by 1,621
Interferons, immunity and cancer immunoediting
Dunn, G. P., Koebel, C. M., & Schreiber, R. D. (2006) · Nature Reviews Immunology · doi:10.1038/nri1961 · Cited by 1,617
Swann, J. B., & Smyth, M. J. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31405 · Cited by 1,447
The IL-17 Family of Cytokines in Health and Disease
McGeachy, M. J., Cua, D. J., & Gaffen, S. L. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.021 · Cited by 1,443
“In addition, as discussed above, IL-17 promotes proliferation of skin epithelial cells to promote tumorigenesis (Chen et al., 2019; Langowski et al., 2006).”
BackgroundMonoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Adenoma–linked barrier defects and microbial products drive IL-23/IL-17-mediated tumour growth
Grivennikov, S. I., Wang, K., Mucida, D., Stewart, C. A., Schnabl, B., Jauch, D., Taniguchi, K., Yu, G.-Y., Österreicher, C. H., Hung, K. E., et al. (2012) · Nature · doi:10.1038/nature11465 · Cited by 1,327
Altered macrophage differentiation and immune dysfunction in tumor development
Sica, A., & Bronte, V. (2007) · Journal of Clinical Investigation · doi:10.1172/jci31422 · Cited by 1,238
The safety and side effects of monoclonal antibodies
Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A., & George, A. J. T. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3003 · Cited by 1,144
Dangerous liaisons: STAT3 and NF-κB collaboration and crosstalk in cancer
Grivennikov, S. I., & Karin, M. (2010) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2009.11.005 · Cited by 1,160
“In recent years, an important protumorigenic role for IL-23 has also emerged (94).”
BackgroundInfluentialIL-10 Family Cytokines IL-10 and IL-22: from Basic Science to Clinical Translation
Ouyang, W., & O’Garra, A. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.020 · Cited by 1,072
Tesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
TH17 cells in development: an updated view of their molecular identity and genetic programming
Dong, C. (2008) · Nature reviews. Immunology · doi:10.1038/nri2295 · Cited by 1,064
Th17 and regulatory T cells in mediating and restraining inflammation
Littman, D. R., & Rudensky, A. Y. (2010) · Cell · doi:10.1016/j.cell.2010.02.021 · Cited by 1,039
Lactate in the Regulation of Tumor Microenvironment and Therapeutic Approaches
de la Cruz-López, K. G., Castro-Muñoz, L. J., Reyes-Hernández, D. O., García-Carrancá, A., & Manzo-Merino, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01143 · Cited by 940
“In addition, lactate produced by the tumor cell promotes the overexpression of IL-23, present in different types of tumors (colon, breast, stomach, melanoma) (156), the presence of this cytokine promotes expression of IL17, Matrix metalloprotease 9 (MMP-9), increases angiogenesis and reduces the infiltration of CD8 in…”
BackgroundCytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Teng, M. W. L., Bowman, E. P., McElwee, J. J., Smyth, M. J., Casanova, J.-L., Cooper, A. M., & Cua, D. J. (2015) · Nature Medicine · doi:10.1038/nm.3895 · Cited by 873
IL-17 can promote tumor growth through an IL-6–Stat3 signaling pathway
Wang, L., Yi, T., Kortylewski, M., Pardoll, D. M., Zeng, D., & Yu, H. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20090207 · Cited by 842
“…role of the immune system in tumor immune surveillance and cancer promotion is exemplified by a pair of related cytokines: although IL-12 clearly possesses antitumor activity via both NK activation and Th1/IFN- induction, IL-23 has been found to promote carcinogenesis (Langowski et al., 2006).”
BackgroundTumor-specific Th17-polarized cells eradicate large established melanoma
Muranski, P., Boni, A., Antony, P. A., Cassard, L., Irvine, K. R., Kaiser, A., Paulos, C. M., Palmer, D. C., Touloukian, C. E., Ptak, K., et al. (2008) · Blood · doi:10.1182/blood-2007-11-120998 · Cited by 845
Kryczek, I., Banerjee, M., Cheng, P., Vatan, L., Szeliga, W., Wei, S., Huang, E., Finlayson, E., Simeone, D., Welling, T. H., et al. (2009) · Blood · doi:10.1182/blood-2009-03-208249 · Cited by 813
T Helper 17 Cells Promote Cytotoxic T Cell Activation in Tumor Immunity
Martin-Orozco, N., Muranski, P., Chung, Y., Yang, X. O., Yamazaki, T., Lu, S., Hwu, P., Restifo, N. P., Overwijk, W. W., & Dong, C. (2009) · Immunity · doi:10.1016/j.immuni.2009.09.014 · Cited by 800
“In contrast to our results, IL-23, important in Th17 cell regulation, has been shown to promote tumor growth and prevent immunosurveillance (Langowski et al., 2006).”
BackgroundResultInfluentialInterleukins in cancer: from biology to therapy
Briukhovetska, D., Dörr, J., Endres, S., Libby, P., Dinarello, C. A., & Kobold, S. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00363-z · Cited by 781
A Human Interleukin-12/23 Monoclonal Antibody for the Treatment of Psoriasis
Krueger, G. G., Langley, R. G., Leonardi, C., Yeilding, N., Guzzo, C., Wang, Y., Dooley, L. T., & Lebwohl, M. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa062382 · Cited by 807
“Re-educating” tumor-associated macrophages by targeting NF-κB
Hagemann, T., Lawrence, T., McNeish, I., Charles, K. A., Kulbe, H., Thompson, R. G., Robinson, S. C., & Balkwill, F. R. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080108 · Cited by 792
TRUCKs: the fourth generation of CARs
Chmielewski, M., & Abken, H. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1046430 · Cited by 738
“Although IL-23 enhances the memory T-cell response as does IL-12 [56], it seems to be less suitable to sustain an antitumor attack since it sustains chronic inflammation and promotes progression of the disease [57].”
BackgroundKastelein, R. A., Hunter, C. A., & Cua, D. J. (2007) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104758 · Cited by 763
“Indeed, we show that IL-23 is significantly upregulated in the overwhelming majority of human carcinoma samples (43).”
BackgroundSelf-citationSandborn, W. J., Feagan, B. G., Fedorak, R. N., Scherl, E., Fleisher, M. R., Katz, S., Johanns, J., Blank, M., & Rutgeerts, P. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.014 · Cited by 753
Lactate dehydrogenase A: A key player in carcinogenesis and potential target in cancer therapy
Feng, Y., Xiong, Y., Qiao, T., Li, X., Jia, L., & Han, Y. (2018) · Cancer Medicine · doi:10.1002/cam4.1820 · Cited by 705
Cytokines in Cancer Immunotherapy
Lee, S., & Margolin, K. (2011) · Cancers · doi:10.3390/cancers3043856 · Cited by 693
“IL-23 has also demonstrated both pro-tumor and anti-tumor effects in different mouse models: IL-23 deficient mice have a decreased incidence of chemically-induced tumors, while increasing IL-23 at the tumor site or systemic IL-23 leads to tumor inhibition and increased survival [174-176].”
BackgroundCancer-related inflammation: Common themes and therapeutic opportunities
Balkwill, F. R., & Mantovani, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.005 · Cited by 685
“For nstance, IL-1 is involved in the generation of IL-17 producing CD+ T ells and the IL-23/IL-17 axis has been shown to promote skin carinogenesis [61].”
BackgroundDual Roles of Immune Cells and Their Factors in Cancer Development and Progression
Zamarron, B. F., & Chen, W. (2011) · International Journal of Biological Sciences · doi:10.7150/ijbs.7.651 · Cited by 681
“IL-23 is another recently identified pro-carcinogenic cytokine, promoting inflammation and angiogenesis within the tumor microenvironment while reducing CD8+ T cell infiltration (38).”
TH17 cells in tumour immunity and immunotherapy
Zou, W., & Restifo, N. P. (2010) · Nature Reviews Immunology · doi:10.1038/nri2742 · Cited by 624
Follicular B helper T cells in antibody responses and autoimmunity
Vinuesa, C. G., Tangye, S. G., Moser, B., & Mackay, C. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1714 · Cited by 624
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Interleukin-12: Biological Properties and Clinical Application
Del Vecchio, M., Bajetta, E., Canova, S., Lotze, M. T., Wesa, A., Parmiani, G., & Anichini, A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0776 · Cited by 601
Wu, P., Wu, D., Ni, C., Ye, J., Chen, W., Hu, G., Wang, Z., Wang, C., Zhang, Z., Xia, W., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.03.013 · Cited by 608
Genetic and biological hallmarks of colorectal cancer
Li, J., Ma, X., Chakravarti, D., Shalapour, S., & DePinho, R. A. (2021) · Genes & Development · doi:10.1101/gad.348226.120 · Cited by 573
“…of the Myc pathway (McCuaig et al. 2020). iLCs regulate bacterial homeostasis and are regulated by the microbiome to produce a variety of cytokines, which can be both protumorigenic and antitumorigenic (Langowski et al. 2006; Geremia et al. 2011; Abt et al. 2012; Sonnenberg and Artis 2012).”
BackgroundChmielewski, M., Kopecky, C., Hombach, A. A., & Abken, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0103 · Cited by 562
“IL-23 moreover sustains inflammatory diseases and thereby promotes tumor progression (30), making IL-23 a less favorite candidate.”
Ostrand-Rosenberg, S., Sinha, P., Beury, D. W., & Clements, V. K. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2012.01.011 · Cited by 583
“IL-23 mediates these effects by driving the proliferation and inflammatory function of Th17 cells [68], which suppress immune surveillance and promote metastasis by impacting adaptive [69] and innate [70] immunity.”
Inflammation and colorectal cancer: colitis-associated neoplasia
Grivennikov, S. I. (2013) · Seminars in Immunopathology · doi:10.1007/s00281-012-0352-6 · Cited by 551
“inflammatory skin tumorigenesis model [118].”
BackgroundNew insights into IL-12-mediated tumor suppression
Tugues, S., Burkhard, S. H., Ohs, I., Vrohlings, M., Nussbaum, K., vom Berg, J., Kulig, P., & Becher, B. (2015) · Cell Death & Differentiation · doi:10.1038/cdd.2014.134 · Cited by 558
“By usingmice lacking IL-23, IL-23 receptor or anti-IL23p19 blocking antibodies, endogenous IL-23 was shown to promote tumor growth in different tumor models.(142,143)”
BackgroundZhang, J.-P., Yan, J., Xu, J., Pang, X.-H., Chen, M.-S., Li, L., Wu, C., Li, S.-P., & Zheng, L. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2008.12.033 · Cited by 535
“Th17 cells have been detected in both murine and human tumors [21–24], but their contribution to tumor pathogenesis remains elusive.”
In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORγt+ T cells
Lochner, M., Peduto, L., Cherrier, M., Sawa, S., Langa, F., Varona, R., Riethmacher, D., Si-Tahar, M., Di Santo, J. P., & Eberl, G. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080034 · Cited by 542
Myc Cooperates with Ras by Programming Inflammation and Immune Suppression
Kortlever, R. M., Sodir, N. M., Wilson, C. H., Burkhart, D. L., Pellegrinet, L., Brown Swigart, L., Littlewood, T. D., & Evan, G. I. (2017) · Cell · doi:10.1016/j.cell.2017.11.013 · Cited by 553
“IL-23 is a pro-inflammatory cytokine that suppresses wound resolution and is pro-tumorigenic in many tissues (Langowski et al., 2006), including lung (Baird et al., 2013).”
BackgroundAment, W., & Verkerke, G. J. (2009) · Sports Medicine · doi:10.2165/00007256-200939050-00005 · Cited by 482
“Langowski et al.([220]) discovered in several human tumours a significant RNA up regulation of IL-23.”
BackgroundPleiotropy and specificity: insights from the interleukin 6 family of cytokines
Murakami, M., Kamimura, D., & Hirano, T. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.027 · Cited by 533
Innate lymphoid cells sustain colon cancer through production of interleukin-22 in a mouse model
Kirchberger, S., Royston, D. J., Boulard, O., Thornton, E., Franchini, F., Szabady, R. L., Harrison, O., & Powrie, F. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.20122308 · Cited by 529
“This was accompanied by increased levels of molecules involved in intestinal epithelial neoplasia, such as the EGFR ligand amphiregulin (Areg), a mediator of proliferation, and the matrix metalloproteinase Mmp9 (Langowski et al., 2006), involved in invasion and angiogenesis, and Hif1a and Vegfa, but not Ptgs2 (Cox2) a…”
BackgroundInfluentialSTAT3 Target Genes Relevant to Human Cancers
Carpenter, R., & Lo, H.-W. (2014) · Cancers · doi:10.3390/cancers6020897 · Cited by 511
“IL-23 is another immune suppressing cytokine that has been shown to reduce tumor infiltration by CD8 + T cells and promote tumor angiogenesis [111].”
BackgroundThe Role of Cytokines in Breast Cancer Development and Progression
Esquivel-Velázquez, M., Ostoa-Saloma, P., Palacios-Arreola, M. I., Nava-Castro, K. E., Castro, J. I., & Morales-Montor, J. (2015) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2014.0026 · Cited by 490
Immune surveillance: a balance between protumor and antitumor immunity
Ostrand-Rosenberg, S. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2007.12.007 · Cited by 480
The Immunobiology of the Interleukin-12 Family: Room for Discovery
Tait Wojno, E. D., Hunter, C. A., & Stumhofer, J. S. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.011 · Cited by 482
“For example, the finding that IL-23p19−/− mice are highly resistant to cancer (Langowski et al., 2006) was unexpected and difficult to reconcile with the ability of IL-23”
Regulation of the IL-23 and IL-12 Balance by Stat3 Signaling in the Tumor Microenvironment
Kortylewski, M., Xin, H., Kujawski, M., Lee, H., Liu, Y., Harris, T., Drake, C., Pardoll, D., & Yu, H. (2009) · Cancer Cell · doi:10.1016/j.ccr.2008.12.018 · Cited by 474
“infiltration of CD8 T cells, IL-23 reduced CD8 T cells in tumor and promoted tumor angiogenesis (Langowski et al., 2006).”
BackgroundInfluentialThe Immunobiology of Interleukin-27
Yoshida, H., & Hunter, C. A. (2015) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112134 · Cited by 467
Haworth, O., Cernadas, M., Yang, R., Serhan, C. N., & Levy, B. D. (2008) · Nature Immunology · doi:10.1038/ni.1627 · Cited by 424
Humoral immunity, inflammation and cancer
Tan, T.-T., & Coussens, L. M. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.01.001 · Cited by 417
IL-17 disrupts corneal barrier following desiccating stress
De Paiva, C. S., Chotikavanich, S., Pangelinan, S. B., Pitcher, J. D., Fang, B., Zheng, X., Ma, P., Farley, W. J., Siemasko, K. F., Niederkorn, J. Y., et al. (2009) · Mucosal Immunology · doi:10.1038/mi.2009.5 · Cited by 422
Phenotypic analysis of prostate-infiltrating lymphocytes reveals TH17 and Treg skewing
Sfanos, K. S., Bruno, T. C., Maris, C. H., Xu, L., Thoburn, C. J., DeMarzo, A. M., Meeker, A. K., Isaacs, W. B., & Drake, C. G. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5164 · Cited by 427
Kryczek, I., Wei, S., Zou, L., Altuwaijri, S., Szeliga, W., Kolls, J., Chang, A., & Zou, W. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.11.6730 · Cited by 416
“Strikingly, it was also reported that IL-23 may promote tumor incidence and growth (14).”
Essentials of Th17 cell commitment and plasticity
Muranski, P., & Restifo, N. P. (2013) · Blood · doi:10.1182/blood-2012-09-378653 · Cited by 383
IL-10 Elicits IFNγ-Dependent Tumor Immune Surveillance
Mumm, J. B., Emmerich, J., Zhang, X., Chan, I., Wu, L., Mauze, S., Blaisdell, S., Basham, B., Dai, J., Grein, J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.11.003 · Cited by 418
“IL-10 Deficiency Increases Tumor Incidence and Decreases Immune Surveillance We subjected wild-type (WT) or IL-10 deficient (IL-10 / ) C57BL/6 mice to a two-step skin carcinogenesis protocol (Langowski et al., 2006).”
BackgroundMethodInfluentialSelf-citationPapp, K. A., Griffiths, C. E. M., Gordon, K., Lebwohl, M., Szapary, P. O., Wasfi, Y., Chan, D., Hsu, M.-C., Ho, V., Ghislain, P. D., et al. (2013) · British Journal of Dermatology · doi:10.1111/bjd.12214 · Cited by 415
CD4 T-cell Subsets and Tumor Immunity: The Helpful and the Not-so-Helpful
Kim, H.-J., & Cantor, H. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0216 · Cited by 380
Rachitskaya, A. V., Hansen, A. M., Horai, R., Li, Z., Villasmil, R., Luger, D., Nussenblatt, R. B., & Caspi, R. R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5167 · Cited by 399
JAK/STAT pathway: Extracellular signals, diseases, immunity, and therapeutic regimens
Hu, Q., Bian, Q., Rong, D., Wang, L., Song, J., Huang, H.-S., Zeng, J., Mei, J., & Wang, P.-Y. (2023) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2023.1110765 · Cited by 339
“IL-6 induces STAT3-mediated Th17 differentiation, which maintains inflammatory responses by releasing IL-17 and IL-23 and causes the secretion of VEGF and TGF in fibroblasts and endothelial cells (Langowski et al., 2006; Wang L. et al., 2009).”
BackgroundObesity predisposes to Th17 bias
Winer, S., Paltser, G., Chan, Y., Tsui, H., Engleman, E., Winer, D., & Dosch, H. ‐. (2009) · European Journal of Immunology · doi:10.1002/eji.200838893 · Cited by 377
Gleason, M. K., Lenvik, T. R., McCullar, V., Felices, M., O'Brien, M. S., Cooley, S. A., Verneris, M. R., Cichocki, F., Holman, C. J., Panoskaltsis-Mortari, A., et al. (2012) · Blood · doi:10.1182/blood-2011-06-360321 · Cited by 373
Protumor vs Antitumor Functions of IL-17
Murugaiyan, G., & Saha, B. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0901017 · Cited by 369
“Although IFN- -secreting Th1 cells and CTLs mediate antitumor immunity, the other T cell subsets such as Foxp3-expressing regulatory T cells (Treg)3 and IL-10-secreting regulatory type 1 (Tr1) cells dampen immunity to tumor-associated Ags and represent the main hurdle in successful antitumor immunotherapy (2–4).”
BackgroundInfluentialChmielewski, M., Hombach, A. A., & Abken, H. (2014) · Immunological Reviews · doi:10.1111/imr.12125 · Cited by 356
“thereby promotes tumor progression (57).”
Prabhala, R. H., Pelluru, D., Fulciniti, M., Prabhala, H. K., Nanjappa, P., Song, W., Pai, C., Amin, S., Tai, Y.-T., Richardson, P. G., et al. (2010) · Blood · doi:10.1182/blood-2009-10-246660 · Cited by 351
Pivotal Role of Innate and Adaptive Immunity in Anthracycline Chemotherapy of Established Tumors
Mattarollo, S. R., Loi, S., Duret, H., Ma, Y., Zitvogel, L., & Smyth, M. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0753 · Cited by 333
He, D., Li, H., Yusuf, N., Elmets, C. A., Li, J., Mountz, J. D., & Xu, H. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902574 · Cited by 334
Tumor promoting role of anti-tumor macrophages in tumor microenvironment
Goswami, K. K., Ghosh, T., Ghosh, S., Sarkar, M., Bose, A., & Baral, R. (2017) · Cellular Immunology · doi:10.1016/j.cellimm.2017.04.005 · Cited by 329
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
Tumor-associated Macrophages (TAM) and Inflammation in Colorectal Cancer
Erreni, M., Mantovani, A., & Allavena, P. (2011) · Cancer Microenvironment · doi:10.1007/s12307-010-0052-5 · Cited by 325
“More recently, Langowski and colleagues [155] instead demonstrated that IL-23 expression is strongly increased in different types of cancer, including colon adenocarcinoma; IL-23 promoted tumor incidence and growth by stimulating inflammatory responses, up-regulation of MMP9, increased angiogenesis and reduced CD8 T-c…”
BackgroundCytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331
The role of IL‐23 and the IL‐23/TH17 immune axis in the pathogenesis and treatment of psoriasis
Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W. H., & Prinz, J. C. (2017) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.14433 · Cited by 313
“animal data in which IL-12–deficient mice are susceptible to chemical carcinogenesis, whereas IL-23–deficient mice are resistant.(131) In patients with solid tumors, 1-year survival was significantly greater in patients with elevated serum levels of IL-12.”
BackgroundTumor microenvironments direct the recruitment and expansion of human Th17 cells
Su, X., Ye, J., Hsueh, E. C., Zhang, Y., Hoft, D. F., & Peng, G. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0902813 · Cited by 324
IL-10: Master Switch from Tumor-Promoting Inflammation to Antitumor Immunity
Oft, M. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0214 · Cited by 322
“Simultaneously, tumor-infiltrating CD8þ T cells and their cytotoxic mediators and IFN-g are highly prevalent (25).”
BackgroundSelf-citationDemonstration of inflammation-induced cancer and cancer immunoediting during primary tumorigenesis
Swann, J. B., Vesely, M. D., Silva, A., Sharkey, J., Akira, S., Schreiber, R. D., & Smyth, M. J. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0708594105 · Cited by 308
Development in Motion: Helper T Cells at Work
Reiner, S. L. (2007) · Cell · doi:10.1016/j.cell.2007.03.019 · Cited by 313
Cancer immunosurveillance, immunoediting and inflammation: independent or interdependent processes?
Bui, J. D., & Schreiber, R. D. (2007) · Current Opinion in Immunology · doi:10.1016/j.coi.2007.02.001 · Cited by 303
Mechanism and uses of a membrane peptide that targets tumors and other acidic tissues in vivo
Andreev, O. A., Dupuy, A. D., Segala, M., Sandugu, S., Serra, D. A., Chichester, C. O., Engelman, D. M., & Reshetnyak, Y. K. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702439104 · Cited by 321
Dual role of macrophages in tumor growth and angiogenesis
Lamagna, C., Aurrand-Lions, M., & Imhof, B. A. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.1105656 · Cited by 311
Durable anticancer immunity from intratumoral administration of IL-23, IL-36γ, and OX40L mRNAs
Hewitt, S. L., Bai, A., Bailey, D., Ichikawa, K., Zielinski, J., Karp, R., Apte, A., Arnold, K., Zacharek, S. J., Iliou, M. S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat9143 · Cited by 316
“Although IL-23 can be associated with TH17–type as well as protumorigenic responses in some contexts [sustained cytokine expression (14, 15)], exogenous introduction induces antitumor immunity in multiple preclinical studies (16).”
BackgroundStromal Cells in the Tumor Microenvironment
Denton, A. E., Roberts, E. W., & Fearon, D. T. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-78127-3_6 · Cited by 306
The IL-23/Th17 axis: therapeutic targets for autoimmune inflammation
Kikly, K., Liu, L., Na, S., & Sedgwick, J. D. (2006) · Current Opinion in Immunology · doi:10.1016/j.coi.2006.09.008 · Cited by 303
Metadata
- Authors
- Langowski, J. L., Zhang, X., Wu, L., Mattson, J. D., Chen, T., Smith, K., Basham, B., McClanahan, T., Kastelein, R. A., & Oft, M.
- Corresponding author
- Oft, Martin
- Venue
- Nature
- Published
- 2006-05-10
- Volume
- 442
- Issue
- 7101
- Pages
- 461-465
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1984467626
- Cited by
- 1,018
- References
- 30
- Citations by year
- 2026: 23 · 2025: 18 · 2024: 32 · 2023: 46 · 2022: 42 · 2021: 44 · 2020: 41 · 2019: 52 · 2018: 41 · 2017: 41 · 2016: 41 · 2015: 47 · 2014: 62 · 2013: 72 · 2012: 65
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Immune cells in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Keywords
- IL-23, tumour-associated inflammation, tumor surveillance, CD8+ T cell infiltration, intraepithelial lymphocytes, tumor microenvironment, angiogenesis, MMP-9, IL-12, chemical carcinogenesis, IL23R, tumor growth, cancer immunotherapy
- MeSH terms
- Animals, Cell Division, Humans, Inflammation, Interleukins, Mice, Inbred C57BL, Neoplasms, Signal Transduction, CD8-Positive T-Lymphocytes, Interleukin-12, Genetic Predisposition to Disease, Mice, Interleukin-23, Interleukin-23 Subunit p19
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.